The investigations target potential breaches of fiduciary duty by boards of directors during the sale or merger processes of these companies. For Arcosa, Inc. (NYSE: ACA), the inquiry follows a proposed sale to CRH Americas, Inc. at $150.00 per share. Similarly, the firm is reviewing the merger between Bio Green Med Solution, Inc. (NASDAQ: BGMS) and Future NRG Sdn. Bhd., alongside the combination of Non-Invasive Monitoring Systems, Inc. (OTCPK: NIMU) and Gravitics, Inc., where shareholders stand to retain a 4.5% stake in the combined entity.
First Seacoast Bancorp, Inc. (NASDAQ: FSEA) faces the most immediate pressure, with a shareholder vote scheduled for August 27, 2026. The proposed sale to Cambridge Financial Group, Inc. offers investors $17.25 per share in cash. Shareholders concerned about the valuation or the integrity of these deals may contact the firm for a review of their rights, as the firm emphasizes its history of litigating securities class actions from its headquarters in the Empire State Building.





Comments (0)
No comments yet. Be the first!